Menopausal Hormone Therapy

Slide 1 · Menopausal Hormone Therapy

Clinicopathologic benefits, adverse effects, and individualized risk

Estrogen withdrawal and symptom burden

Evidence from the Women’s Health Initiative

Breast, endometrial, vascular, and skeletal consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Explain the symptomatic and tissue effects of declining estrogen at menopause.

Distinguish combined estrogen–progestin therapy from estrogen-only therapy.

Interpret the main benefits and adverse outcomes reported in the Women’s Health Initiative.

Explain why age, timing, duration, regimen, and route modify risk.

Apply the source evidence to brief clinical risk–benefit scenarios.

Slide 3 · The central clinical problem

CONCEPTUAL SEQUENCE

Estrogen declines

Menopausal symptoms and bone loss

Hormone therapy improves selected outcomes

Exogenous exposure creates competing risks

Schematic — simplified teaching model

Slide 4 · Menopause: The initiating endocrine change

Circulating estrogen levels decline as females approach menopause.

Symptoms may involve thermoregulation and the lower genitourinary tract.

Long-term estrogen deficiency is associated with skeletal and other health effects.

The clinical challenge is to relieve symptoms without creating avoidable treatment-related harm.

Slide 5 · Symptom domains of estrogen withdrawal

Vasomotor

Hot flashes

Night sweats

Symptoms prompting consideration of MHT

Genitourinary

Vaginal dryness

Urinary urgency and frequency

Recurrent urinary tract infections

Slide 6 · Vasomotor symptoms: The original treatment target

Hot flashes and night sweats are prominent menopausal complaints.

Relief of these symptoms was an early rationale for systemic hormone therapy.

The presence of symptoms does not establish that systemic therapy is suitable for every patient.

Safety decisions must separately account for cancer and vascular risks.

Slide 7 · Genitourinary symptoms have a distinct profile

Vaginal dryness can coexist with urinary urgency and frequency.

Recurrent urinary-tract infections are included among the menopausal-associated symptoms.

Symptom domain matters when evaluating therapeutic goals.

Systemic MHT risk; It does not provide a detailed local-treatment algorithm in this section.

Slide 8 · Consequences linked to estrogen deficiency

Domain

Robbins-described association

Teaching interpretation

Bone

Increased osteoporosis risk

Bone preservation is a potential MHT benefit.

Cardiovascular

Higher cardiovascular disease risk

Association does not prove that MHT prevents events.

Cognition

Cognitive decline in aging females

MHT is not recommended to prevent dementia.

Symptoms

Vasomotor and genitourinary symptoms

Symptom control is the primary clinical indication discussed.

Slide 9 · What menopausal hormone therapy means

MHT administers exogenous hormonal agents to address menopausal symptoms.

Older terminology: Hormone replacement therapy.

The most common systemic regimen combines an estrogen with progesterone or a synthetic progestin.

Estrogen-only therapy is described for females who have undergone hysterectomy.

Slide 10 · Why a progestogen is added

CONCEPTUAL SEQUENCE

Estrogen exposure

Proliferative signal in intact endometrium

Unopposed stimulation increases hyperplasia/cancer concern

Progestogen added to the regimen

Schematic — simplified teaching model

Slide 11 · Treatment choice begins with uterine status

Uterus present

Estrogen exposure raises a uterine cancer concern.

The common regimen contains estrogen and a progestogen.

Endometrial risk must remain part of monitoring and counseling.

After hysterectomy

The uterine cancer rationale for a progestogen no longer applies.

Estrogen alone in this group.

Other risks still need assessment.

Slide 12 · Unopposed estrogen: A pathologic mechanism

Prolonged estrogenic stimulation favors glandular proliferation in the endometrium.

Exogenous estrogen is among the associations of endometrial hyperplasia.

Hyperplasia is an important cause of abnormal uterine bleeding.

Some hyperplastic lesions are precursors to endometrioid endometrial carcinoma.

Slide 13 · Endometrial proliferation: Conceptual morphology

SCHEMATIC — NOT A HISTOLOGIC SPECIMEN

Less crowded glandular arrangement

Hyperplasia: Crowding of glands

Purpose: Illustrate relative gland crowding, not diagnose atypia

Slide 14 · Two hyperplasia morphologies

Without atypia

Increased gland-to-stroma ratio

Variable gland size and shape

Stroma generally remains between glands

Atypical hyperplasia / EIN

Complex crowded glands

Nuclear atypia is present

Substantial morphologic overlap with low-grade carcinoma

Slide 15 · Endometrial risk is biologically plausible

CONCEPTUAL SEQUENCE

Persistent estrogenic stimulation

Endometrial gland proliferation

Hyperplasia may develop

Atypical hyperplasia can be a precursor to carcinoma

Schematic — source-based conceptual sequence

Slide 16 · Keep prevention distinct from symptom treatment

Relief of menopausal symptoms is different from preventing long-term disease.

Early MHT use was also promoted for bone, coronary, and cognitive outcomes.

Those presumed preventive advantages required testing in prospective trials.

Robbins does not recommend MHT for cardiovascular disease or dementia prevention.

Slide 17 · Before the Women’s Health Initiative

Initial clinical studies suggested slower postmenopausal bone loss.

Other early reports suggested fewer myocardial infarctions.

A reduction in cognitive decline was also proposed.

These beliefs helped broaden MHT use beyond immediate symptoms.

Slide 18 · Evidence forced reassessment

CONCEPTUAL SEQUENCE

Early promising observations

Prospective placebo-controlled WHI trial

Benefits and adverse outcomes assessed together

Routine preventive MHT claims reassessed

Schematic — source-based conceptual sequence

Slide 19 · WHI: What was studied

The initial WHI findings were published in 2002.

The cited trial was large, prospective, and placebo controlled.

Approximately 17,000 participants were studied.

The examined regimen combined conjugated equine estrogens with medroxyprogesterone acetate.

Slide 20 · WHI inference: Specify the exposure

The trial result concerns a particular estrogen–progestin formulation.

It should not be silently equated with every dose, route, and hormonal preparation.

Age at initiation and baseline risk may also change treatment effects.

Robbins explicitly emphasizes this heterogeneity when reappraising MHT.

Slide 21 · WHI reported fewer fractures

Skeletal protection was observed

MHT reduced fractures among participants receiving therapy.

This positive finding coexisted with significant adverse outcomes.

A fracture benefit alone cannot establish a favorable overall risk–benefit balance.

Slide 22 · WHI identified increased breast cancer risk

Combination therapy carried a cancer signal

Breast cancer risk increased during combination MHT.

The increase after a median exposure of 5–6 years.

Therapy duration therefore matters when interpreting risk.

Slide 23 · WHI identified increased stroke risk

Vascular outcomes altered the benefit–risk assessment

The combination-therapy trial reported more strokes.

Later analyses emphasize risk differences by age and treatment route.

A possible subgroup benefit does not negate this adverse-event signal.

Slide 24 · WHI identified increased VTE risk

Venous thrombosis is a major safety domain

Combination therapy increased venous thromboembolism.

Deep vein thrombosis and pulmonary embolism are included.

Risk is higher in patients with additional prothrombotic factors.

Slide 25 · WHI coronary finding was not preventive

No reduction in coronary heart disease incidence

The original combination-therapy trial did not lower CHD incidence.

Later analyses suggest age and timing modify cardiovascular effects.

MHT is not recommended as primary prevention of cardiovascular disease.

Slide 26 · The initial WHI outcome pattern

Outcome

Reported effect of combined therapy

Interpretive consequence

Fractures

Reduced

A demonstrable skeletal benefit

Breast cancer

Increased

Relevant to longer use

Stroke

Increased

Major vascular harm

Venous thromboembolism

Increased

Assess thrombosis risk

Coronary heart disease

No reduction in incidence

Not a coronary prevention strategy

Slide 27 · Practice changed after WHI

TREATMENT USE (%)

Before the marked decline

22%

2010

4.7%

A decline in MHT use from 22% to 4.7% by 2010. The first percentage is not assigned an exact calendar year in the text.

Slide 28 · Declining MHT use and breast cancer diagnoses

The sharp decrease in MHT use was accompanied by an apparent decline in newly diagnosed breast cancers.

Robbins also notes changed screening patterns in older females.

Concurrent trends support a hypothesis but do not alone prove an individual-level causal effect.

The prospective WHI findings provide stronger evidence for the treatment-related signal.

Slide 29 · Modern interpretation: Five effect modifiers

CONCEPTUAL SEQUENCE

Hormone regimen

Age and baseline risk

Time since menopause

Treatment duration

Dose, formulation, and route

Schematic — source-based conceptual sequence

Slide 30 · Combined and estrogen-only regimens

Estrogen + progestogen

Used with an intact uterus

WHI combined-therapy breast cancer signal

Results cannot automatically represent estrogen-alone therapy

Estrogen alone

Used after hysterectomy

Different risk profile may apply

Requires separate assessment of vascular and other effects

Slide 31 · Why duration must be explicit

Breast cancer risk with combined therapy is described after a median 5–6 years.

Venous thrombosis risk appears especially pronounced in the first 2 years.

Different harms therefore have different time courses.

A single duration label cannot summarize all organ-specific risks.

Slide 32 · Do not confuse cancer endpoints

Organ

What Robbins states

What cannot be inferred

Breast

Combined MHT increases risk after median 5–6 years.

All hormone regimens have identical risk.

Ovary

No increased ovarian cancer risk in this MHT summary.

The treatment prevents ovarian cancer.

Uterus

Unopposed estrogen raises uterine cancer concern.

A hysterectomy removes systemic vascular risks.

Slide 33 · Breast cancer risk: A clinicopathologic reading

Exogenous hormonal therapy is listed among breast cancer risk factors.

Population incidence shifts can be affected by changes in mammographic screening.

The combination-therapy trial establishes an adverse signal under its studied exposure.

Avoid treating one relative-risk association as a personalized absolute prediction.

Slide 34 · Early and later initiation differ

Initiated below age 60

MHT may have favorable effects on atherosclerosis and coronary disease.

Baseline risk and healthy endothelium appear important.

Not a recommendation for preventive MHT.

Initiated after age 60

Greater CHD risk.

Stroke and VTE risk are also increased.

An older age at initiation changes the balance.

Slide 35 · The cardiovascular timing hypothesis

CONCEPTUAL SEQUENCE

Earlier menopause / healthier vessels

Estrogen receptor response in endothelium

Potentially different vascular effect

Different effect with later initiation

Schematic — simplified teaching model

Slide 36 · Healthy vascular endothelium matters

Potential benefit in younger women partly to endothelial estrogen-receptor responses.

Age at treatment initiation is therefore more than an administrative variable.

Atherosclerosis and pre-existing vascular risk may alter the response to the same hormone exposure.

The timing hypothesis remains distinct from proof of clinical prevention.

Slide 37 · Cardiovascular prevention is not an indication

A favorable subgroup hypothesis is not clinical prophylaxis

Initial WHI did not show fewer CHD events with combination therapy.

Later analyses identify age-related effect modification.

Robbins explicitly advises against MHT to prevent cardiovascular disease.

Slide 38 · Venous thromboembolism: Clinical meaning

VTE encompasses deep venous thrombosis and pulmonary embolism.

MHT-associated excess thrombosis may have severe consequences.

Risk is greater when estrogen exposure coexists with other prothrombotic conditions.

Assessment must examine both medication and host factors.

Slide 39 · Two-hit model of VTE susceptibility

CONCEPTUAL SEQUENCE

Hormone-related prothrombotic effect

Inherited or acquired risk factor

Combined tendency toward venous clotting

DVT ± pulmonary embolism

Schematic — simplified teaching model

Slide 40 · VTE is especially important early in treatment

The MHT-associated increase as more pronounced in the first 2 years.

An early uneventful interval does not establish long-term freedom from risk.

Timing of therapy and duration should both be documented.

Risk review should precede treatment initiation.

Slide 41 · Factor V Leiden as a risk modifier

Factor V Leiden is an inherited predisposition to venous thrombosis.

Its mechanism involves resistance to inactivation by activated protein C.

It as a MHT risk-enhancing hypercoagulable state.

A genetic predisposition may interact with acquired exposures.

Slide 42 · Prothrombin G20210A is another modifier

The prothrombin gene variant is associated with increased prothrombin levels.

Prothrombin mutations among MHT-related hypercoagulable risk conditions.

Risk is not binary: Thrombophilic traits may coexist with immobility and treatment exposure.

Do not infer that all carriers develop thrombosis.

Slide 43 · Immobilization and MHT can interact

CONCEPTUAL SEQUENCE

Underlying thrombophilia (if present)

Immobility or venous stasis

Hormonal exposure

Cumulative predisposition to VTE

Schematic — source-based conceptual sequence

Slide 44 · Keep venous and arterial outcomes separate

Venous thrombosis

DVT and pulmonary embolism

Strong interaction with thrombophilia and immobility

Risk appears especially pronounced early

Stroke / coronary events

Arterial clinical endpoints

Affected by age and vascular disease status

Do not infer identical mechanisms or risk size

Slide 45 · Why administration route is relevant

CONCEPTUAL SEQUENCE

Oral estrogen

Hepatic first-pass exposure

Metabolic / coagulation-related differences

Potentially different vascular risk

Schematic — simplified teaching model

Slide 46 · Oral versus transdermal estrogen

Oral route

Passes through the liver first

First-pass metabolism can raise triglyceride levels

VTE/stroke risk appears relatively higher

Transdermal route

Avoids hepatic first-pass exposure

Appears to carry lower VTE/stroke risk

May be preferred with obesity or high triglycerides

Slide 47 · Route differences are not guarantees

The source uses qualified wording: VTE and stroke risks “appear” lower with transdermal estrogen.

Avoid translating this into “no vascular risk.”

Dose, formulation, age, and background risk remain relevant.

The clinical comparison is qualitative in the supplied section.

Slide 48 · Obesity and high triglycerides change route choice

Obesity and high triglyceride levels as reasons transdermal therapy may be preferred.

First-pass hepatic metabolism is an important rationale for route-dependent effects.

These features are considered alongside pre-existing thrombosis risk.

They should not be reduced to a single universal treatment rule.

Slide 49 · Estrogen helps preserve skeletal mass

CONCEPTUAL SEQUENCE

Estrogen signaling

Reduced osteoblast apoptosis / increased osteoclast apoptosis

Suppression of RANKL production

Lower relative bone resorption

Schematic — simplified teaching model

Slide 50 · Estrogen deficiency increases bone turnover

CONCEPTUAL SEQUENCE

Menopause → lower estrogen

RANKL rises; Osteoprotegerin falls

Osteoclast recruitment/activity increases

Resorption exceeds formation

Schematic — source-based conceptual sequence

Slide 51 · Why postmenopausal osteoporosis develops

Bone formation and bone resorption both increase with estrogen deficiency.

Resorption dominates, producing high-turnover osteoporosis.

The cancellous compartment of vertebral bodies is particularly affected.

Loss of trabecular connectivity explains mechanical fragility.

Slide 52 · Trabecular connectivity determines strength

SCHEMATIC — NOT A MICROGRAPH OR QUANTITATIVE MEASURE

Connected trabecular framework

Postmenopausal bone loss

Progressive thinning and disconnection increase fragility

Slide 53 · Osteoporosis: The pathology is loss of bone quantity

Histologically normal bone is present in reduced quantity.

Trabecular plates become thin and can lose interconnections.

Microfractures and vertebral collapse may follow.

The phenomenon is not a mineralization disorder such as osteomalacia.

Slide 54 · Skeletal consequences have clinical weight

Vertebral fractures may cause pain, reduced height, and spinal deformity.

Hip, pelvic, and spinal fractures can produce prolonged immobility.

Immobilization itself can lead to serious complications.

WHI fracture reduction therefore represents a clinically meaningful treatment effect.

Slide 55 · Bone assessment is a separate clinical task

Plain radiographs are insensitive until substantial bone mass is lost.

Dual-energy x-ray absorptiometry measures bone mineral density.

Normal serum calcium does not exclude osteoporosis.

Fracture risk cannot be evaluated from menopausal symptoms alone.

Slide 56 · Other approaches to bone preservation

Intervention category

Examples described by Robbins

Relation to MHT

Activity and nutrition

Exercise; adequate calcium and vitamin D

Support skeletal health independent of MHT.

Antiresorptive medication

Bisphosphonates

Nonhormonal fracture-prevention options.

Targeted antiresorptive

Denosumab (anti-RANKL)

Addresses osteoclast signaling.

MHT

Estrogen agonist treatment

Bone benefit constrained by vascular hazards.

Slide 57 · MHT for osteoporosis requires selective judgment

Bone benefit does not erase systemic harm

Robbins recognizes fracture reduction and slowed bone loss.

Deep vein thrombosis and stroke limit estrogen use for bone treatment.

MHT may be appropriate for prevention of osteoporosis in selected females.

Slide 58 · A practical risk–benefit matrix

Variable

Potentially favorable context

Cautionary context

Symptoms

Bothersome menopausal symptoms

No symptomatic indication

Age / timing

Below 60; within 10 years of menopause

Initiation after 60

Thrombosis

No recognized major thrombotic risk

VTE risk, thrombophilia, immobilization

Route

Transdermal may fit selected risk profiles

Assuming all routes are equivalent

Goal

Symptom treatment; selected bone prevention

CVD or dementia prophylaxis

Slide 59 · Clinical decision sequence

CONCEPTUAL SEQUENCE

Identify symptom burden and treatment goal

Document uterine status / select regimen

Assess age, interval since menopause, and risks

Select route and plan for reassessment

Schematic — simplified teaching model

Slide 60 · The early symptomatic patient

Robbins supports a role for systemic agents in early symptomatic menopause.

The described favorable context includes age below 60 years and less than 10 years since menopause.

The patient should lack major contraindicating vascular risk factors.

A decision remains individualized rather than automatic.

Slide 61 · Why later initiation is different

Increased CHD risk when therapy begins after age 60.

Stroke and VTE risks are also increased with later initiation.

The timing hypothesis discourages projecting young-cohort findings onto older patients.

Initiating MHT solely to prevent chronic disease is not supported.

Slide 62 · Treatment duration: The source recommendation

An initial treatment period followed by reassessment.

Its stated consensus is to taper oral agents at 3–5 years.

This is a textbook summary, not a substitute for a current individualized clinical guideline.

The duration of exposure should be recorded alongside the reason for continuing therapy.

Slide 63 · When symptoms persist

A possible move to transdermal therapy if symptoms persist after oral treatment.

Route change may address some, but not all, risk concerns.

Review the original indication, age, and intervening vascular risk factors.

Do not equate symptom persistence with an absence of treatment harm.

Slide 64 · Case: Vasomotor symptoms with an intact uterus

CLINICAL VIGNETTE

A 53-year-old with disruptive hot flashes is considering systemic menopausal hormone therapy. She has an intact uterus.

Which medication-design feature follows directly from uterine status?

SOURCE-BASED DISCUSSION

A progestogen is ordinarily paired with estrogen.

The rationale is endometrial protection from prolonged estrogenic stimulation.

Vascular and breast risk require independent assessment.

Slide 65 · Case: Symptoms after hysterectomy

CLINICAL VIGNETTE

A 52-year-old, previously treated by hysterectomy, seeks relief from menopausal vasomotor symptoms.

How does the absence of the uterus change regimen logic?

SOURCE-BASED DISCUSSION

Estrogen-only therapy after hysterectomy.

Removal of uterine risk does not eliminate breast or vascular questions.

Age, route, duration, and baseline risk still matter.

Slide 66 · Case: Inherited thrombophilia

CLINICAL VIGNETTE

A 56-year-old with vasomotor symptoms has a known factor V Leiden variant and is planning an extended period of immobilization.

What risk interaction is most important?

SOURCE-BASED DISCUSSION

Inherited thrombophilia and immobilization both predispose to venous thrombosis.

Systemic estrogen exposure adds a treatment-related risk concern.

The scenario argues against treating age alone as sufficient risk assessment.

Slide 67 · Case: MHT initiation at older age

CLINICAL VIGNETTE

A 68-year-old with no vasomotor complaints asks for MHT to prevent myocardial infarction and cognitive decline.

Does the supplied Robbins evidence support this goal?

SOURCE-BASED DISCUSSION

No: MHT is not recommended for CVD or dementia prevention.

Starting after 60 is associated with increased CHD and other vascular risk.

Therapeutic goals must be separated from unproven preventive claims.

Slide 68 · Case: Osteoporosis as the primary concern

CLINICAL VIGNETTE

A 58-year-old asks whether MHT is the preferred universal therapy to prevent fragility fractures.

What is the clinicopathologic trade-off?

SOURCE-BASED DISCUSSION

Estrogen can reduce resorption and WHI reported fewer fractures.

VTE and stroke limit indiscriminate estrogen treatment.

Selective use and other bone-directed approaches.

Slide 69 · Common misinterpretations and corrections

Misinterpretation

Source-consistent correction

“WHI showed MHT has no benefits.”

Fractures decreased; several major adverse events increased.

“All preparations have identical risks.”

Regimen, age, duration, dose, and route matter.

“Starting early prevents heart disease.”

Possible timing effects do not justify CVD prevention.

“Transdermal estrogen cannot cause VTE.”

Risk appears lower, not absent.

“Uterine status is irrelevant.”

Estrogen-alone therapy is reserved for hysterectomy in Robbins.

Slide 70 · Five durable principles

Treat menopausal symptoms—not an assumed cardiovascular or cognitive prevention benefit.

Protect the intact endometrium from unopposed estrogenic exposure.

Balance fracture reduction against breast, thrombotic, and stroke outcomes.

Specify regimen, initiation age, baseline risk, duration, and route.

Reassess rather than treating hormone exposure as a permanent default.

Slide 71 · Source foundation and evidence boundaries

PRIMARY TEXTBOOK AND CROSS-CHAPTER CONTEXT

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026).

Primary teaching section: Environmental and Nutritional Diseases — Menopausal Hormone Therapy.

Integrated parent context: adverse drug reactions; cross-chapter biology of endometrial hyperplasia, thrombosis, and osteoporosis.

The chapter PDF was not supplied; source statements were checked against the available extracted Robbins Markdown.

No current external clinical guideline or independent WHI paper was used to alter the textbook’s recommendations.